{
      "note": "Imported from Universal Publishings (OAI id oai:ojs.pkp.sfu.ca:article/17883)",
      "date_type": "published",
      "metadata_visibility": "show",
      "ispublished": "pub",
      "subjects": [
        "CRISPR-Cas9",
        "Gene Editing",
        "Casgevy",
        "Sickle Cell Disease",
        "Base Editing"
      ],
      "official_url": "https://universalpublishings.com/index.php/siad/article/view/17883",
      "userid": 1,
      "id_number": "oai:ojs.pkp.sfu.ca:article/17883",
      "full_text_status": "none",
      "type": "article",
      "date": "2026-04-23",
      "uri": "https://arxiv.universalpublishings.com/id/eprint/87615",
      "eprintid": 87615,
      "creators": [
        {
          "name": {
            "lineage": null,
            "family": "Jain",
            "honourific": null,
            "given": "Dr Saloni"
          }
        },
        {
          "name": {
            "given": "Jawed",
            "honourific": null,
            "lineage": null,
            "family": "Akhtar"
          }
        },
        {
          "name": {
            "given": "Ramdev",
            "honourific": null,
            "family": "Siyag",
            "lineage": null
          }
        },
        {
          "name": {
            "given": "Mohd",
            "honourific": null,
            "family": "Danis",
            "lineage": null
          }
        },
        {
          "name": {
            "family": "Anas",
            "lineage": null,
            "given": "Mohd",
            "honourific": null
          }
        }
      ],
      "abstract": "Gene editing represents one of the most transformative biotechnologies of the 21st century, offering unprecedented precision in modifying DNA to treat genetic diseases, enhance agricultural productivity, and potentially alter the trajectory of human evolution. This narrative article explores the revolutionary CRISPR-Cas9 technology, its clinical applications including the landmark FDA approval of Casgevy for sickle cell disease, emerging ethical frameworks, and the regulatory landscape shaping this rapidly evolving field. With the global gene editing market projected to reach $45 billion by 2035 , understanding this technology's capabilities, limitations, and societal implications has never been more critical.",
      "status_changed": "2026-05-26 16:23:00",
      "title": "THE GENETIC REVOLUTION: How CRISPR and Gene Editing Are Reshaping Medicine, Ethics, and Our Future",
      "eprint_status": "archive",
      "publication": "SYNAPSES: INSIGHTS ACROSS THE DISCIPLINES",
      "lastmod": "2026-05-26 16:23:00",
      "sword_depositor": 1,
      "dir": "disk0/00/08/76/15",
      "keywords": "CRISPR-Cas9; Gene Editing; Casgevy; Sickle Cell Disease; Base Editing",
      "publisher": "Research Science and Innovation House",
      "rev_number": 1,
      "datestamp": "2026-05-26 16:23:00"
    }